Amicogen Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
18,884
13,779
30,811
14,264
22,233
Total Accounts Receivable
8,380
13,273
21,291
19,278
15,188
Inventories
1,541
2,671
28,656
18,712
26,687
Other Current Assets
234
699
777
2,802
8,436
Total Current Assets
29,039
30,423
81,535
55,056
72,544
Net Property, Plant & Equipment
13,927
17,239
53,852
63,226
64,784
Total Investments and Advances
-
3,882
6,572
6,440
5,020
Long-Term Note Receivable
-
-
236
146
56
Intangible Assets
1,329
2,823
17,649
19,992
17,648
Other Assets
66
-
-
1,471
1,543
Total Assets
44,361
54,367
159,844
146,330
163,515
ST Debt & Current Portion LT Debt
-
80
23,582
19,378
21,938
Accounts Payable
225
1,552
16,330
7,563
9,697
Income Tax Payable
1,090
1,144
204
59
-
Other Current Liabilities
1,353
1,254
6,515
8,530
13,706
Total Current Liabilities
2,668
4,030
46,631
35,530
45,342
Long-Term Debt
-
-
1,950
3,250
1,400
Provision for Risks & Charges
100
174
234
75
759
Deferred Taxes
128
144
142
25
1,921
Other Liabilities
74
-
642
292
92
Total Liabilities
2,970
4,348
49,598
39,172
47,592
Common Equity (Total)
41,391
49,733
82,104
81,537
89,190
Total Shareholders' Equity
41,391
49,733
82,104
81,537
89,190
Total Equity
41,391
50,020
110,246
107,158
115,922
Liabilities & Shareholders' Equity
44,361
54,367
159,844
146,330
163,515
Accumulated Minority Interest
-
287
28,141
25,622
26,732

About Amicogen

View Profile
Address
64 Dongbu-ro 1259 beon-gil
Jinju SG 52621
Korea, Republic Of
Employees -
Website http://www.amicogen.com
Updated 09/14/2018
Amicogen, Inc. engages in the development and marketing of enzyme products and functional food materials. Its products include specialty enzyme for pharmaceutical, food, feed and industrial; new bio-ingredient such as natural health ingredients for food, feed and cosmetics, finished products; and immunological products such as protein A resin, anticancer treatment vaccine based on B cell and mononuclear cell, and POCT immune diagnosis device using innovative C-ECL technology. It also engages in original equipment manufacturing and original development manufacturing of nutraceutical products.